X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
hiv infections - drug therapy (12) 12
female (11) 11
index medicus (11) 11
male (11) 11
adult (10) 10
human immunodeficiency virus--hiv (10) 10
middle aged (10) 10
viral load (9) 9
treatment outcome (8) 8
antiretroviral drugs (7) 7
drug therapy (7) 7
hiv infection (7) 7
infectious diseases (7) 7
medicine, general & internal (7) 7
dosage and administration (6) 6
hiv (6) 6
infectious disease (6) 6
internal medicine (6) 6
abridged index medicus (5) 5
aged (5) 5
antiretroviral therapy (5) 5
antiviral agents (5) 5
cd4 lymphocyte count (5) 5
drug resistance (4) 4
drug therapy, combination (4) 4
emtricitabine (4) 4
hiv infections - virology (4) 4
hiv-1 - drug effects (4) 4
hiv-1-infected patients (4) 4
immunology (4) 4
patients (4) 4
safety (4) 4
tenofovir (4) 4
therapy (4) 4
acquired immune deficiency syndrome--aids (3) 3
aids/hiv (3) 3
anti-hiv agents - administration & dosage (3) 3
antiretroviral agents (3) 3
clinical trials (3) 3
comorbidity (3) 3
complications and side effects (3) 3
darunavir (3) 3
drug administration schedule (3) 3
hiv-1 (3) 3
infected patients (3) 3
infection (3) 3
infections (3) 3
life sciences (3) 3
protease inhibitors (3) 3
raltegravir potassium (3) 3
randomization (3) 3
ritonavir (3) 3
young adult (3) 3
adolescent (2) 2
adults (2) 2
anti-hiv agents - therapeutic use (2) 2
anti-retroviral agents - therapeutic use (2) 2
antiretroviral-naive adults (2) 2
care and treatment (2) 2
cd4 antigen (2) 2
combination therapy (2) 2
deoxyribonucleic acid--dna (2) 2
double-blind (2) 2
double-blind method (2) 2
drug therapy, combination - methods (2) 2
drug-resistance (2) 2
efficacy (2) 2
france (2) 2
hepatitis (2) 2
highly active antiretroviral therapy (2) 2
hiv infections - complications (2) 2
hiv infections - epidemiology (2) 2
hiv infections - immunology (2) 2
hiv integrase inhibitors - administration & dosage (2) 2
hiv integrase inhibitors - therapeutic use (2) 2
immune activation (2) 2
immunodeficiency-virus type-1 (2) 2
inhibitors (2) 2
integrase inhibitor raltegravir (2) 2
kaplan-meier estimate (2) 2
laboratories (2) 2
leukocytes, mononuclear - virology (2) 2
maraviroc intensification (2) 2
markers (2) 2
medical research (2) 2
mortality (2) 2
motivation (2) 2
mutation (2) 2
once-daily dolutegravir (2) 2
prevalence (2) 2
pyrrolidinones - therapeutic use (2) 2
research (2) 2
reverse-transcriptase inhibitor (2) 2
ribonucleic acid--rna (2) 2
risk (2) 2
ritonavir - administration & dosage (2) 2
ritonavir - adverse effects (2) 2
ritonavir - therapeutic use (2) 2
rna, viral - drug effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2109 - 2117
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 4, pp. 387 - 396
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9569, pp. 1261 - 1269
Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANTIRETROVIRAL DRUGS | THERAPY | HIV-1-INFECTED INDIVIDUALS | INFECTION | DRUG-RESISTANCE | PREVALENCE | ENFUVIRTIDE | HIV-1 | Drug Resistance, Multiple | Humans | Middle Aged | Male | HIV Integrase Inhibitors - administration & dosage | Viral Load | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | Atazanavir Sulfate | Adult | Female | Raltegravir Potassium | Organic Chemicals - administration & dosage | Pyridines - therapeutic use | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Logistic Models | Treatment Outcome | Pyrrolidinones | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Pyridines - pharmacology | Oligopeptides - pharmacology | Viral drug resistance | Care and treatment | Dosage and administration | Drug therapy | HIV infection | Raltegravir | Design | Studies | Antiretroviral drugs | Plasma | Inhibitor drugs | Protease inhibitors | Conferences | Human immunodeficiency virus--HIV | Mortality | Gene expression | Drug resistance | Patients | RNA-directed DNA polymerase | Laboratories | Toxicity | Viruses | Genomes | Randomization | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Safety | Drug dosages | Integrase | Phenotypes | Effectiveness | Proteinase inhibitors | Ribonucleic acid--RNA | Antiretroviral therapy | CD4 antigen | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Nucleosides | Index Medicus | Abridged Index Medicus
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2015, Volume 2, Issue 8, pp. e319 - e327
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9568, pp. 1169 - 1178
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2015, Volume 2, Issue 3, pp. e82 - e91
Journal Article
The Lancet, ISSN 0140-6736, 08/2018, Volume 392, Issue 10148, pp. 685 - 697
The benefits of combination antiretroviral therapy (cART) for HIV replication and transmission control have led to its universal recommendation. Many people... 
REVERSE-TRANSCRIPTASE INHIBITOR | MEDICINE, GENERAL & INTERNAL | TENOFOVIR DISOPROXIL FUMARATE | ONCE-DAILY DOLUTEGRAVIR | BROADLY NEUTRALIZING ANTIBODIES | DEMAND PREEXPOSURE PROPHYLAXIS | ATAZANAVIR/RITONAVIR PLUS LAMIVUDINE | CO-FORMULATED ELVITEGRAVIR | HUMAN-IMMUNODEFICIENCY-VIRUS | ANTIRETROVIRAL-NAIVE ADULTS | HELPER T-CELLS | HIV Infections - prevention & control | Anti-Retroviral Agents - therapeutic use | Sexually Transmitted Diseases - virology | HIV Infections - epidemiology | Humans | Cost of Illness | Male | Global Health - education | Sexually Transmitted Diseases - prevention & control | Life Expectancy - trends | HIV - drug effects | Anti-HIV Agents - administration & dosage | Drug Therapy, Combination - methods | Comorbidity - trends | Global Health - statistics & numerical data | Survival Analysis | Anti-HIV Agents - therapeutic use | Female | HIV - genetics | HIV Infections - drug therapy | HIV Infections - transmission | Africa South of the Sahara - epidemiology | Infectious Disease Transmission, Vertical - prevention & control | Viral antibodies | Highly active antiretroviral therapy | Medical research | Antiviral agents | AIDS vaccines | AIDS treatment | Comorbidity | Communicable diseases | Medicine, Experimental | Antibodies | HIV (Viruses) | Antiretroviral drugs | Therapy | Life expectancy | Health risks | Antiretroviral therapy | Disease transmission | Immune checkpoint | Life span | Acquired immune deficiency syndrome--AIDS | Womens health | Antiretroviral agents | Human immunodeficiency virus--HIV | Cardiovascular diseases | Heart diseases
Journal Article
Journal Article